PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth similar to GNPX's 100.00%. Walter Schloss might infer both firms share similar operational efficiencies.
-121.69%
Negative operating income growth while GNPX is at 100.00%. Joel Greenblatt would press for urgent turnaround measures.
-139.60%
Negative net income growth while GNPX stands at 8.45%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-131.82%
Negative EPS growth while GNPX is at 75.93%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-131.82%
Negative diluted EPS growth while GNPX is at 75.93%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-31.70%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while GNPX stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.37%
10Y OCF/share CAGR in line with GNPX's 91.28%. Walter Schloss would see both as similarly efficient over the decade.
75.95%
5Y OCF/share CAGR at 75-90% of GNPX's 95.79%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
7.00%
3Y OCF/share CAGR under 50% of GNPX's 92.02%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
81.58%
Net income/share CAGR at 75-90% of GNPX's 95.91%. Bill Ackman would press for strategic moves to boost long-term earnings.
47.75%
Below 50% of GNPX's 96.74%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-122.09%
Negative 3Y CAGR while GNPX is 94.57%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-94.45%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
58.16%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-73.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Negative asset growth while GNPX invests at 45.71%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-21.56%
We have a declining book value while GNPX shows 69.85%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-8.90%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
60.05%
We increase R&D while GNPX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
231.77%
We expand SG&A while GNPX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.